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Abstract  
AIM: To evaluate the relationship of apelin and nitric oxide (NO) to endothelial dysfunction in type 1 diabetics. 
PATIENTS AND METHODS: Sixty two type 1 diabetics and 30 healthy age and sex matched controls were 
included. Blood samples for apelin, NO, glycosylated hemoglobin (HbA1c), and lipid profile were collected. 
Albumin/creatinine ratio was assessed in urine. Flow mediated dilatation (FMD) via ultrasound was done.  
RESULTS: The mean age of diabetics were 16.3 ± 1.5 yrs (14.0 – 19.0 yrs), and duration of disease, were 9.4 ± 
2.9 yrs (5.0 – 16.5 yrs). FMD and FMD/nitrate mediated dilatation (NMD) ratio were lower in diabetics. NO was 
decreased, while apelin and albumin/creatinine ratio were increased significantly in diabetics. There was a 
positive correlation between apelin and HbA1c. On the contrary, NO had a negative correlation with HbA1c, 
albumin/creatinine ratio, LDL-c and OxLDL.  
CONCLUSION: Diabetic patients had endothelial dysfunction and high apelin level, with no related to each other. 
High level of apelin is associated with bad glycemic control. Obesity had no role to increase in apelin level. NO is 
related to diabetic nephropathy and atherosclerosis. We recommend a further large study to evaluate the 
relationship of apelin with endothelial dysfunction. 
 
 
 
 
Introduction 
 
Apelin, a recently described adipocytokine, is 
abundantly expressed in adipose tissue and produced 
in many body parts by the endothelial cells [1, 2]. It is 
synthesized as a prepropeptide then modified into 
smaller peptides with higher potency. It produces its 
effects through a cell surface G protein-coupled 
receptor called APJ, which is structurally similar to 
angiotensin receptor [3]. In obese persons with 
hyperinsulinemia, apelin levels are increased [4]. 
Levels are decreased in patients with dyslipidemia 
and newly diagnosed and untreated type 2 diabetes 
mellitus (T2DM) [5, 6]. 
Apart from insulin deficiency, insulin 
resistance is found in type 1 diabetes mellitus (T1DM), 
both at onset and course of the disease [7, 8]. Insulin 
resistance is also found in obesity making it a risk 
factor for T1DM in children in addition to type II DM [9-
13]. Obese infants have higher risk for T1DM in 
chidhood [14]. This may be due to the harmful effects 
to the beta cells early in life as a result of the relative 
hyperinsulinemia induced by the increased demands 
in obesity [13, 15, 16]. 
There is endothelial dysfunction with 
increased cardiovascular risk in type 1 diabetes. L-
Arginine is converted to nitric oxide (NO), which is an 
important mediator of vascular homeostasis due to its 
central role in the maintenance of the endothelial 
milieu [17, 18].  
Cohen [19], reported endothelial dysfunction 
is the earliest event in the atherosclerotic process and 
Järvisalo et al. [20], found impaired FMD response is 
a common manifestation in children with type 1 
diabetes and associated with high carotid artery IMT, 
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suggesting that endothelial dysfunction in with type 1 
diabetics may predispose them to the development of 
early atherosclerosis. 
  We are aim to evaluate apelin and nitric 
oxide (NO) in type 1 diabetic patients and its relation 
to vascular affection as well as to evaluate the 
relationship between apelin and the glycemic balance. 
 
 
Patients and Methods 
 
Patients 
The study included 62 adolescent patients 
with type 1 diabetes mellitus (DM) among those 
attending to the endocrine clinic, National Research 
Centre. The control group consisted of 30 age and 
sex matched healthy normal volunteers. Control group 
was the healthy friends or relatives of our patients.  
Inclusion criteria: children with type 1 DM, 
duration of disease > 5 years, patients age > 14 and < 
19 yrs old. We selected this young age group with 
short duration of diabetes firstly, to explore whether 
early atherosclerotic changes starts at this early age 
shortly after onset of diabetes or needs longer 
exposure to the diabetic milieu and secondly because 
in younger age group (< 14 yrs old) atherosclerotic 
lesions are expected to be in the form of microscopic 
intimal fatty streaks that is too minute to be resolved 
by ultrasonography.  
Exclusion criteria were: patients during acute 
diabetic complications e.g. diabetic ketoacidosis 
(DKA) or hypoglycemia, patients suffering from 
cardiac diseases e.g. congenital, rheumatic heart, left 
ventricular dysfunction, patients on metformin or 
multivitamins and smokers.  
 
Study design and protocol  
It is a cross-sectional observational study 
done after obtaining approval from the ethical 
committee of the National Research Centre, Cairo, 
Egypt. Registration number is 11052. Written informed 
consent was obtained from all patients or their parents 
and controls after full discussion about the aim of the 
study. This study is a part of a project done in the 
National Research Centre for evaluation of cardiac, 
vascular and endothelial function in adolescent type 1 
diabetic patients.  
All the studied patients were subjected to: 
history taking including: age of patients, sex, age of 
onset of diabetes, duration of diabetes, type and dose 
of insulin therapy, family history of diabetes; and we 
asked about presence of any symptoms of cardiac, 
renal, neurological affection or presence of any type of 
autonomic dysfunction. We also asked about history 
of taking drugs other than insulin.  
 
Clinical examination 
I. Patients and controls were subjected to 
general, cardiac, chest and neurological examination.  
II. Blood pressure was measured three times 
for patients and controls after 5-minute rest in the 
sitting position on both upper limbs with the use of 
automatic manometer (Omron M4 Plus, Omron Health 
care Europe, Hoof drop, and Holland). The mean 
value of the second and the third measurement was 
calculated. The measurements taken on the dominant 
limb were analyzed.  
III. Anthropometric measurements in the form 
of weight, height, waist circumference (WC), and hip 
circumference (HC) were taken for each participant. 
The weight and height of the participants were 
measured up to 0.01 kg and 0.1 cm using a Seca 
Scale Standing Balance and a Holtain Portable 
Anthropometer (Holtain, Ltd, Crymmych, Wales, U.K.). 
Body mass index (BMI) was calculated as weight (in 
kilograms) divided by height (in meters) squared. 
Waist circumference was measured at the level of the 
umbilicus with the participant standing and breathing 
normally; hip circumference was measured at the 
level of the iliac crest, using non stretchable plastic 
tape to the nearest 0.1 cm. The waist / hip ratio and 
waist / height ratio (cm/ cm) were calculated. Each 
measurement was taken as the mean of three 
consecutive measurements, using standardized 
equipment [21, 22]. The landmarks, instruments used, 
and techniques followed were those recommended by 
the international biological program [21, 22]. 
 
Laboratory investigation  
Simultaneously all patients and controls 
underwent the following tests:  
All patients and controls underwent the 
following tests: For cholesterol measurements, 
venous blood was sampled after a 12-h fast. Serum 
total cholesterol was determined by a commercial kit 
(Boehringer-Mannheim, Germany) [23]. High-density 
lipoprotein (HDL) cholesterol was separated from the 
serum by precipitation of the other lipoproteins with a 
heparin/manganese procedure [24]. Low-density 
lipoprotein (LDL) cholesterol was calculated using the 
Friedewald equation. The concentration of 
triglycerides(Tg) was measured in a TechnoCon 
AutoAnalyzer II (TechnoCon Instruments, Tarrytown, 
NY, USA). 
Glycosylated hemoglobin (HbA1c) was done 
every 3 months and the mean value was calculated 
per year. It was measured using high pressure liquid 
chromatography (Nichols Institute, Van Nuys, CA, 
USA) [25]. 
Screening for microalbuminuria was assessed 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  936                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
in fresh morning urine samples by measuring 
albumin/creatinine ratio by enzyme linked 
immunosorbent assay (ELISA) kit provided by 
Orgentec Diagnostika, Gmbh (Mainz, Germany) [26]. 
Serum concentrations of oxidized low-density 
lipoprotein (OxLDL) were detected by commercially 
available solid phase two-site enzyme immunoassay 
kit (Mercodia AB, Uppsala, Sweden). Measurements 
of the OxLDL levels in the sera were performed 
according to the recommendations of the 
manufacturer. The intra and interassay coefficients of 
variations were 5.5% – 7.3% and 4.0% – 6.2%, 
respectively, and the sensitivity was < 1 mU/L. 
Nitric oxide production in sera was measured 
using a nitric oxide colorimetric assay kit (Roche cat 
No. 11756281001). Sera was irradiated and then 
filtered in a 10,000 kd MWCO column (Satorious, 
Vivascience cat No. 13239-E). The assay was 
conducted as per the manufacturer’s instructions 
using a NO control with a standard curve plotted and 
samples were measured at a 550 nm wavelength. 
Serum apelin-12 concentration were measured using 
a commercial enzyme – liked immunosorbent assay 
(Phoenix Pharmaceuticals Inc. Burlingame,CA,USA). 
 
Flow mediated dilatation (FMD) 
All imaging studies were performed by the 
same vascular sonographer & the same 
ultrasonographic machine using (General Electric 
medical ultrasonographic machine model: Vivid 7 Pro, 
GE Vingmed ultrasound AS-Nl90, Horton-Norway 
equipped with 7.5–10 MHz linear-array transducer) 
after the published protocols [27-29]. With the subject 
lying in the supine position, ECG electrodes were 
placed on the chest; the machine automatically 
measured and recorded results of the 
electrocardiogram. All measurements were made at 
end diastole to avoid possible errors resulting from 
variable arterial compliance. A sphygmomanometer 
cuff was placed on the proximal right arm. The right 
brachial artery images were obtained 3 cm proximal to 
the elbow crease using B-mode imaging in the 
longitudinal plane of the artery. A baseline image was 
acquired using a resolution box function to magnify 
this part of the artery. Blood flow was estimated by the 
pulsed Doppler velocity signal obtained from a mid-
artery sample volume. The cuff was inflated to 100 
mm Hg above the systolic pressure to occlude arterial 
flow for 5 min. The cuff was then deflated, and the 
longitudinal image of the brachial artery was recorded 
immediately & continuously for 60 seconds after cuff 
deflation for greatest response guided by the 
hyperemic flow detected by pulsed Doppler. Flow-
mediated dilation (FMD) was assessed by 
measurement of the greatest brachial artery diameter 
that was detected at 60 seconds after release of the 
cuff in most cases. The subject then had a rest for 30 
min, after which a sublingual dose of nitroglycerin 
tablet (Dinitra, isosorbidedinitrate 5 mg manufactured 
by Egyptian int. pharmaceutical industries co., tenth of 
Ramadan city, A.R.E., under license of RHONE 
POULENC, PARIS FRANCE) was then administered, 
and the brachial artery response (endothelium-
independent dilation) was assessed by imaging the 
artery continuously for 3 min after the nitroglycerin 
dose for greatest response. 
Measurements of the brachial artery luminal 
diameter were performed on-line at end-diastole, 
coinciding with the onset of the R-wave on the ECG. 
For each phase (baseline, endothelium-dependent 
dilation, and endothelium-independent dilation), three 
brachial artery diameter measurements were obtained 
manually online with electronic calipers and averaged 
from the longitudinal image by identifying the lumen-
intima interface. The largest reading for FMD post-
ischemia {100 × [diameter (1 min)–diameter 
(basal)]/diameter (basal)} was used to represent 
spontaneous endothelial function. In addition, 
nitroglycerine-mediated dilatation (NTG) {100 × [the 
largest reading of diameter (after sublingual 
isosorbidedinitrate–diameter (basal)]/diameter (basal)} 
was assessed. The diameter percent change caused 
by endothelium-dependent flow-mediated dilatation 
(%FMD) and non-endothelium dependent dilatation 
(%NMD) were expressed as the percent change 
relative to that at the initial resting scan.  
Significant endothelial dysfunction was 
defined as FMD < 10% and NMD > 10% [30]. In order 
to increase the sensitivity and specificity of the 
technique for endothelial dysfunction, FMD over NMD 
of the brachial artery < 0.70 defined endothelial 
dysfunction [31]. 
 
Statistical Analysis 
Statistical analysis was conducted using 
Statistical Package for Social Science (SPSS) 
program version 15.0 (Chicago, Illinois, USA). t –test 
or Mann Whitney-U (for none symmetrically 
distributed data) for independent variables was done. 
Pearson’s correlation was also done. 
 
 
Results 
 
Our research included 62 type1 diabetic 
patients (31 females and 31 males) and 30 normal 
controls (15 females and 15 males). Their  mean age 
were 16.3 ± 1.5 yrs and mean duration of diabetes 
were 9.4 ± 2.9 yrs. HbA1, albumin/.creatinine ratio, 
cholesterol, Tg, LDL, OxLDL and apelin were 
significantly increased, in the   contrary,  nitric oxide, 
FMD, and FMD/NMD were decreased significantly in 
diabetics (Table 1).  
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Table 1: Comparison between demographic, laboratory data, 
carotid intimal medial thickness and resistivity index of 
diabetic patients and controls 
Variables 
Patients Controls 
P-value Mean SD Mean SD 
Age (yrs) 16.32 1.52 16.13 2.63 0.70 
Anthropometric data: 
     BMI (kg/m
2
) 24.91 4.20 24.76 5.67 0.8 
BMI (SDS) 24 
    Waist circumference (cm) 83.60 9.39 84.78 12.25 0.60 
HIP circumference (cm) 91.69 8.37 91.20 11.93 0.80 
Waist / hip ratio 0.91 0.06 0.93 0.05 0.20 
Waist / height ratio 0.51 0.06 0.52 0.08 0.90 
Blood pressure: 
     Systolic blood pressure 
(mmHg) 119.35 12.53 118.21 14.42 0.70 
Diastolic blood pressure 
(mmHg) 81.94 9.20 78.57 6.51 0.05 
Laboratory data: 
     HbA1 (%) 9.55 1.90 5.43 0.65 0.0001 
Albumin/ creatinine ratio (µg/ 
g creatinine) 
28.4 
78.33 ± 100.65 
(5.8 – 384.2) 
10.7 
11.28 ± 4.23 
(5.4 – 23.2) 0.0001# 
Total cholesterol (mg/dl) 188.81 63.77 100.54 20.41 0.0001 
Triglyceride (mg/dl) 103.46 78.29 68.89 28.39 0.03 
HDL-c (mg/dl) 51.77 20.58 52.21 11.12 0.90 
LDL-c (mg/dl) 118.66 47.53 62.50 19.88 0.0001 
OxLDL (mg/l) 17.56 6.45 9.06 3.92 0.0001 
Nitric oxide (µmol/l) 28.42 7.06 40.33 6.32 0.0001 
Apelin 223.95  185.83  70.45  27.74  0.0001  
Doppler on brachial artery 
     Brachial artery at rest, mm 3.42 0.39 3.26 0.79 0.2 
Brachial artery (Shill test) 
(FMD), % 10.35 7.16 15.64 10.77 0.005 
Brachial artery after nitrate 
(NMD), % 14.48 6.89 18.14 10.77 0.1 
FMD/NMD 0.82 0.66 2.26 6.29 0.03 
t- test for independent variables; # Mann Whitney U test was used; Median, mean ± SD 
(range). BMI = body mass index; HbA1 = glycosylated hemoglonin; LDL = Low density 
lipoprotein; HDL = high density lipoprotein; OLDL = oxidized low density lipoprotein. 
 
 
Apelin had a significant positive correlation 
with HbA1c (Table 2). 
Table 2: Correlation between demographic, anthropometric, 
laboratory data and flow mediated dilatation and Apelin of 
diabetic patients 
Variables 
Apelin 
r P-value 
Age (yrs) 0.14 0.30 
Duration of diabetes (yrs) -0.05 0.72 
Systolic blood pressure (mmHg) 0.17 0.22 
Diastolic blood pressure (mmHg) 0.21 0.12 
BMI (kg/m
2
) -0.05 0.72 
BMI (SDS) -0.06 0.65 
Waist/ hip ratio 0.15 0.28 
Waist / height ratio -0.03 0.81 
HbA1 (%) 0.26 0.04 
Albumin / creatinine ratio (µg/g creatinine) -0.05 0.74 
Cholesterol (mg/dl) 0.02 0.91 
Triglycerid (mg/dl) -0.03 0.84 
HDL-c (mg/dl) 0.06 0.67 
LDL-c (mg/dl) 0.07 0.64 
VLDL (mg/dl) 0.42 0.10 
oxldl (mg/dl) -0.11 0.44 
Nitric oxide 0.05 0.74 
Doppler on brachial artery at rest (mm) 0.08 0.55 
Doppler on brachial artery (Shill test) (FMD)(%) -0.04 0.76 
Doppler on brachial artery after nitroglycerine (NMD) (%) 0.17 0.22 
 
On the other hand, NO had a negative 
correlation with HbA1c, albumin/creatinine ratio, LDL-
c and OxLDL (Table 3). 
 
 
Discussion 
 
In the current study, diabetic patients had 
higher HbA1c, albumin/creatinine ratio, lipid profile, 
OxLDL and lower NO, FMD and FMD/NMD. This is 
comparable with the study of Schulze el al., [32], who 
reported that the earliest functional atherosclerotic 
changes in the arterial wall is the endothelial 
dysfunction due to impaired endothelial release of 
nitric oxide detected by measuring flow mediated 
dilatation (FMD) of the brachial artery for measuring 
arterial diameter in response to increased flow. 
Table 3: Correlation between demographic, anthropometric, 
laboratory data and flow mediated dilatation and nitric oxide of 
diabetic patients 
Variables 
Nitric oxide 
r P-value 
Age (yrs) 0.04 0.75 
Duration of diabetes (yrs) -0.23 0.07 
Systolic blood pressure (mmHg) 0.13 0.34 
Diastolic blood pressure (mmHg) 0.13 0.31 
BMI (kg/m2) 0.15 0.25 
BMI (SDS) 0.18 0.17 
Waist/ hip ratio -0.02 0.90 
Waist / height ratio -0.09 0.49 
HbA1(%) -0.30 0.02 
Albumin / creatinine ratio (µg/g creatinine) -0.55 0.0001 
Cholesterol (mg/dl) -0.10 0.47 
Triglycerid (mg/dl) -0.16 0.22 
HDL-c (mg/dl) 0.16 0.23 
LDL-c (mg/dl) -0.26 0.05 
VLDL (mg/dl) -0.43 0.07 
OxLDL(mg/dl) -0.32 0.01 
Apelin (ng/ml) 0.05 0.74 
Doppler on brachial artery at rest (mm) 0.08 0.53 
Doppler on brachial artery (Shill test  (FMD)(%) 0.05 0.73 
 
Reduction of NO may be a result of either 
decreased production because of decreased activity 
and/.or reduced expression of eNOS, or low activity of 
NO, or a result of high degradation by high production 
of superoxide ions or reactive oxygen species [17, 
33]. 
In the present study, NO showed a negative 
correlation with HbA1c, albumin/creatinine ratio, LDL-
c, and OxLDL. NO in type 1 diabetics affect heart and 
kidney in the previous studies. Endothelial function 
affected by several factors associated with diabetes, 
including severity of hyperglycemia, duration of 
diabetes, and increase of advanced glycosylated end 
products, microalbuminuria and nephropathy [18].  
 In the present study, the attenuated FMD 
response in diabetic children coincide with the results 
of Wiltshire et al., [34] and Donaghue et al., [35], who 
studied flow-mediated dilation in diabetic children and 
demonstrated attenuated endothelial function in 
diabetic children compared with controls. 
In our study, apelin is increased in diabetic 
patients with a positive correlation with HbA1c. On the 
other hand, it had no significant correlation with 
anthropometric measurement, lipid profile, NO and 
FMD. 
Apelin mRNA is found in many tissues 
including central nervous system (CNS), lung, heart, 
placenta, mammary gland and gastrointestinal tract 
(GIT) [37, 38]. Apelin is an adipokine secreted and 
produced by white adipose tissue in mice and 
humans. It is also included in cardiovascular function. 
Apelin plays a role in the CNS and regulation of food 
intake and water balance. In the contrary, results of 
the other studies are confusing [39, 40]. 
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Apelin has a role in energy metabolism: as it 
improves sensitivity of insulin in insulin-resistant 
obese mice, and it is related to an increase in glucose 
uptake in skeletal muscle [41, 42]. Synthesis of apelin 
is affected by insulin and plasma apelin levels and it is 
increased in obesity in association with 
hyperinsulinaemia [43]. In our study, apelin had a 
significant correlation with glycosylated hemoglobin. 
The relationship of apelin and diabetes in 
humans are still controversial. On the other hand, 
increased apelin level in obese subjects and type 2 
diabetics were reported in some studies. Whereas 
other authors revealed decrease apelin in obese 
subjects with newly-diagnosed type 2 diabetes [44-
48]. 
We found that a very limited study was done 
to assess apelin concentrations in type 1 diabetes. 
Two studies reported increase in apelin in type 1 
diabetics, one of them was in children [49] and the 
other one was in adults [50]. On the other hand, a new 
study revealed that apelin levels is the same in 
diabetics and no diabetics [51]. In our study, we found 
that although apelin concentrations were increased, it 
had no relation to body mass index in diabetic 
patients. This means that obesity is not the main 
factor affecting apelin levels in diabetic patients which 
is in agreement with other studies [38, 44, 45, 52]. 
We conclude that apelin concentrations were 
increased in diabetic patients and it is affected by 
obesity. It is related to glycaemic balance and even 
insulin sensitivity. Diabetic patients had endothelial 
dysfunction and elevation of apelin, but they does not 
related to each other. NO is related to diabetic 
nephropathy and atherosclerosis.  
Further large study is recommended to detect 
the relationship of apelin with vascular affection by 
assessing large number of diabetics with and without 
complication. Apelin is a beneficial adipokine and is a 
promising therapeutic target in metabolic disorders as 
it had anti diabetic properties. 
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